Patent · US Active

RAR selective agonists in combination with immune modulators for cancer immunotherapy

US10363272B2 · kind B2 · utility

9Cited by
23References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 30, 2018
Grant dateJul 30, 2019
Priority date—
Expiry dateAug 30, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2501/385
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.